← Leaderboards
John H Sampson
Duke University
$43,413,436
Attributed
$46,265,441
Total exposure
38
Grants
34
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.8M · FY2005–23$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$72,623,237 · 40
By mechanism
P50$26,439,842 · 12
R01$19,248,630 · 11
P01$16,157,398 · 4
U01$5,214,517 · 1
R42$2,000,000 · 1
R21$1,936,901 · 5
Top collaborators
- Francis Ali-Osman9 shared
- Duane A. Mitchell6 shared
- Hai Yan4 shared
- David M. Ashley2 shared
- Peter Fecci2 shared
- Qijing Li2 shared
- Nancie Maciver2 shared
Most similar at Duke University
Same institution · by research overlap
- Matthias Gromeier$11,871,021
- Darell D Bigner$25,397,506
- David Reardon$8,732,934
- Yiping Yang$13,692,641
- Duane A. Mitchell$34,257,734
Others in their field
Top investigators on “Brain Neoplasms”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$98,312,615
- Gregory H Reaman · National Childhood Cancer Foundation$78,833,655
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- Robert H Vonderheide · University Of Pennsylvania$60,987,353
Research focus
Brain NeoplasmsBrainGlioblastomaTumorAntigensVaccinesPrimary Brain NeoplasmsImmunotherapyT-LymphocyteMalignant - DescriptorImmune ResponseMalignant Neoplasm Of BrainClinical TrialsResponseToxic EffectVaccinationMelanomaNeoplastic CellTumor AntigensCessation Of LifeClinical ResearchDoseMalignant NeoplasmsPrograms
Grant awards (160)
Neoantigen immunotherapy in brain tumors using anti-CD27 to deplete regulatory T cells selectively$254,856
P50 · FY2023 · CA · contact PI
Career Enhancement Program$108,043
P50 · FY2023 · CA · contact PI
Clinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine Efficacy$400,950
R01 · FY2022 · CA · contact PI
Clinical Neuroimmunology of Vaccines in Brain Tumors$400,733
R01 · FY2022 · NS · contact PI
Administrative Core$340,445
P50 · FY2022 · CA · contact PI
Neoantigen immunotherapy in brain tumors using anti-CD27 to deplete regulatory T cells selectively$294,300
P50 · FY2022 · CA · contact PI
Administrative Core$170,427
P01 · FY2022 · CA · contact PI
Developmental Research Program$109,666
P50 · FY2022 · CA · contact PI
Career Enhancement Program$107,660
P50 · FY2022 · CA · contact PI
Metabolic reprogramming to improve EGFRvIII CAR T cell persistence$1
R21 · FY2022 · CA · contact PI
Experimental Therapy for Brain Tumors$2,542,342
P01 · FY2021 · CA · contact PI
Duke SPORE in Brain Cancer$1,432,302
P50 · FY2021 · CA · contact PI
Project 1: Targeting cytomegalovirus antigens in glioblastoma with regulatory T cell depletion$631,432
P01 · FY2021 · CA · contact PI
Clinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine Efficacy$565,025
R01 · FY2021 · CA · contact PI
Clinical Neuroimmunology of Vaccines in Brain Tumors$400,801
R01 · FY2021 · NS · contact PI
CCL3 as a Developmental Therapeutic to Enhance Brain Tumor Therapy$347,813
R01 · FY2021 · NS · contact PI
Administrative Core$232,568
P50 · FY2021 · CA · contact PI
Neoantigen immunotherapy in brain tumors using anti-CD27 to deplete regulatory T cells selectively$199,901
P50 · FY2021 · CA · contact PI
Metabolic reprogramming to improve EGFRvIII CAR T cell persistence$184,717
R21 · FY2021 · CA · contact PI
Administrative Core$175,339
P01 · FY2021 · CA · contact PI
NINDS Research Education Programs for Residents and Fellows in Neurosurgery$166,148
R25 · FY2021 · NS · contact PI
Developmental Research Program$75,426
P50 · FY2021 · CA · contact PI
Career Enhancement Program$73,788
P50 · FY2021 · CA · contact PI
Experimental Therapy for Brain Tumors$2,536,844
P01 · FY2020 · CA · contact PI
Duke SPORE in Brain Cancer$1,984,462
P50 · FY2020 · CA · contact PI
Project 1: Targeting cytomegalovirus antigens in glioblastoma with regulatory T cell depletion$691,384
P01 · FY2020 · CA · contact PI
Clinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine Efficacy$584,463
R01 · FY2020 · CA · contact PI
CCL3 as a Developmental Therapeutic to Enhance Brain Tumor Therapy$347,813
R01 · FY2020 · NS · contact PI
Administrative Core$320,803
P50 · FY2020 · CA · contact PI
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)$269,745
R01 · FY2020 · CA
Neoantigen immunotherapy in brain tumors using anti-CD27 to deplete regulatory T cells selectively$252,322
P50 · FY2020 · CA · contact PI
Administrative Core$173,038
P01 · FY2020 · CA · contact PI
Project 3 Supplement - A Novel Cellular Tumor Vaccine Strategy for Mutant IDH1 glioma$160,934
P50 · FY2020 · CA · contact PI
Developmental Research Program$104,273
P50 · FY2020 · CA · contact PI
Career Enhancement Program$101,659
P50 · FY2020 · CA · contact PI
NINDS Research Education Programs for Residents and Fellows in Neurosurgery$78,885
R25 · FY2020 · NS · contact PI
Experimental Therapy for Brain Tumors$2,461,078
P01 · FY2019 · CA · contact PI
Duke SPORE in Brain Cancer$2,087,874
P50 · FY2019 · CA · contact PI
Human EGFRvIII-specific BiTE for the treatment of Glioblastoma$871,073
U01 · FY2019 · NS · contact PI
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)$677,349
R01 · FY2019 · CA
Project 1: Targeting cytomegalovirus antigens in glioblastoma with regulatory T cell depletion$668,450
P01 · FY2019 · CA · contact PI
Clinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine Efficacy$413,970
R01 · FY2019 · CA · contact PI
CCL3 as a Developmental Therapeutic to Enhance Brain Tumor Therapy$347,813
R01 · FY2019 · NS · contact PI
Administrative Core$335,213
P50 · FY2019 · CA · contact PI
Neoantigen immunotherapy in brain tumors using anti-CD27 to deplete regulatory T cells selectively$256,082
P50 · FY2019 · CA · contact PI
Administrative Core$165,709
P01 · FY2019 · CA · contact PI
Developmental Research Program$109,668
P50 · FY2019 · CA · contact PI
Career Enhancement Program$106,564
P50 · FY2019 · CA · contact PI
Duke SPORE in Brain Cancer$2,300,000
P50 · FY2018 · CA · contact PI
Experimental Therapy for Brain Tumors$2,170,371
P01 · FY2018 · CA · contact PI
Human EGFRvIII-specific BiTE for the treatment of Glioblastoma$1,012,736
U01 · FY2018 · NS · contact PI
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)$703,160
R01 · FY2018 · CA
Development of a Therapeutic for Brain Tumor Immunotherapy$543,119
R01 · FY2018 · CA · contact PI
Project 1: Targeting cytomegalovirus antigens in glioblastoma with regulatory T cell depletion$532,398
P01 · FY2018 · CA · contact PI
Intracerebrally delivered EGFRvIII-targeted CARs for brain tumors$390,265
P50 · FY2018 · CA · contact PI
Peptide Vaccination Targeting Tumor-Specific IDH1R132H Mutation for Brain Tumors$358,971
P50 · FY2018 · CA · contact PI
CCL3 as a Developmental Therapeutic to Enhance Brain Tumor Therapy$347,813
R01 · FY2018 · NS · contact PI
Administrative Core$249,789
P50 · FY2018 · CA · contact PI
Administrative Core$150,536
P01 · FY2018 · CA · contact PI
Duke SPORE in Brain Cancer$2,298,025
P50 · FY2017 · CA · contact PI
Human EGFRvIII-specific BiTE for the treatment of Glioblastoma$1,736,476
U01 · FY2017 · NS · contact PI
Therapeutic Vaccine Targeting CMV Antigens in Glioblastoma$772,615
R42 · FY2017 · CA · contact PI
Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells$447,602
R01 · FY2017 · CA · contact PI
EGFRvIII-targeted Bispecific T cell Engagers for brain tumors$397,908
R01 · FY2017 · NS · contact PI
Intracerebrally delivered EGFRvIII-targeted CARs for brain tumors$361,290
P50 · FY2017 · CA · contact PI
CCL3 as a Developmental Therapeutic to Enhance Brain Tumor Therapy$347,813
R01 · FY2017 · NS · contact PI
Brain Tumor Targeting Using Tumor-Specific Neuroimmunology$347,813
R01 · FY2017 · NS · contact PI
Peptide Vaccination Targeting Tumor-Specific IDH1R132H Mutation for Brain Tumors$333,602
P50 · FY2017 · CA · contact PI
Administrative Core$231,514
P50 · FY2017 · CA · contact PI
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)$185,105
R01 · FY2017 · CA
Duke SPORE in Brain Cancer$2,036,564
P50 · FY2016 · CA · contact PI
Human EGFRvIII-specific BiTE for the treatment of Glioblastoma$1,024,390
U01 · FY2016 · NS · contact PI
Targeting Immunosuppression Pathways to Enhance Brain Tumor Immunotherapy$639,245
P01 · FY2016 · CA · contact PI
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)$616,384
R01 · FY2016 · CA
Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells$499,514
R01 · FY2016 · CA · contact PI
EGFRvIII-targeted Bispecific T cell Engagers for brain tumors$403,487
R01 · FY2016 · NS · contact PI
Brain Tumor Targeting Using Tumor-Specific Neuroimmunology$347,813
R01 · FY2016 · NS · contact PI
Intracerebrally delivered EGFRvIII-targeted CARs for brain tumors$309,514
P50 · FY2016 · CA · contact PI
Peptide Vaccination Targeting Tumor-Specific IDH1R132H Mutation for Brain Tumors$284,697
P50 · FY2016 · CA · contact PI
Administrative Core$198,101
P50 · FY2016 · CA · contact PI
NINDS Research Education Programs for Residents and Fellows in Neurosurgery$63,302
R25 · FY2016 · NS · contact PI
Duke SPORE in Brain Cancer$2,185,000
P50 · FY2015 · CA · contact PI
Therapeutic Vaccine Targeting CMV Antigens in Glioblastoma$1,227,385
R42 · FY2015 · CA · contact PI
Targeting Immunosuppression Pathways to Enhance Brain Tumor Immunotherapy$640,259
P01 · FY2015 · CA · contact PI
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)$634,471
R01 · FY2015 · CA
Human EGFRvIII-specific BiTE for the treatment of Glioblastoma$569,842
U01 · FY2015 · NS · contact PI
Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells$514,429
R01 · FY2015 · CA · contact PI
EGFRvIII-targeted Bispecific T cell Engagers for brain tumors$373,133
R01 · FY2015 · NS · contact PI
Brain Tumor Targeting Using Tumor-Specific Neuroimmunology$347,448
R01 · FY2015 · NS · contact PI
Intracerebrally delivered EGFRvIII-targeted CARs for brain tumors$332,072
P50 · FY2015 · CA · contact PI
Peptide Vaccination Targeting Tumor-Specific IDH1R132H Mutation for Brain Tumors$305,449
P50 · FY2015 · CA · contact PI
Administrative Core$212,538
P50 · FY2015 · CA · contact PI
NINDS Research Education Programs for Residents and Fellows in Neurosurgery$45,870
R25 · FY2015 · NS · contact PI
Duke SPORE in Brain Cancer$2,162,000
P50 · FY2014 · CA · contact PI
Targeting Immunosuppression Pathways to Enhance Brain Tumor Immunotherapy$667,257
P01 · FY2014 · CA · contact PI
Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells$485,104
R01 · FY2014 · CA · contact PI
EGFRvIII-targeted Bispecific T cell Engagers for brain tumors$419,152
R01 · FY2014 · NS · contact PI
Brain Tumor Targeting Using Tumor-Specific Neuroimmunology$343,438
R01 · FY2014 · NS · contact PI
Intracerebrally delivered EGFRvIII-targeted CARs for brain tumors$328,217
P50 · FY2014 · CA · contact PI
Peptide Vaccination Targeting Tumor-Specific IDH1R132H Mutation for Brain Tumors$302,291
P50 · FY2014 · CA · contact PI
Administrative Core$210,341
P50 · FY2014 · CA · contact PI
NINDS Research Education Programs for Residents and Fellows in Neurosurgery$87,114
R25 · FY2014 · NS · contact PI
Targeting Immunosuppression Pathways to Enhance Brain Tumor Immunotherapy$729,405
P01 · FY2013 · CA · contact PI
EGFRvIII-targeted Bispecific T cell Engagers for brain tumors$411,170
R01 · FY2013 · NS · contact PI
Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells$374,823
R01 · FY2013 · CA · contact PI
ENHANCING GLIOMA IMMUNOTHERAPY WITH TEMODAR-INDUCED LYMPHOPENIA AND A MULTIVALENT$205,204
P50 · FY2013 · NS · contact PI
NINDS Research Education Programs for Residents and Fellows in Neurosurgery$69,879
R25 · FY2013 · NS · contact PI
NINDS Research Education Programs for Residents and Fellows in Neurosurgery$1,620
R25 · FY2013 · NS · contact PI
NINDS Research Education Programs for Residents and Fellows in Neurosurgery$1
R25 · FY2013 · NS · contact PI
RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells$452,151
R01 · FY2012 · CA · contact PI
Targeting Immunosuppression Pathways to Enhance Brain Tumor Immunotherapy$411,884
P01 · FY2012 · CA · contact PI
CMV Therapeutic Vaccine for the Treatment of Glioblastoma$246,026
R41 · FY2012 · CA · contact PI
ENHANCING GLIOMA IMMUNOTHERAPY WITH TEMODAR-INDUCED LYMPHOPENIA AND A MULTIVALENT$214,513
P50 · FY2012 · NS · contact PI
NINDS Research Education Programs for Residents and Fellows in Neurosurgery$60,084
R25 · FY2012 · NS · contact PI
NINDS Research Education Programs for Residents and Fellows in Neurosurgery$1
R25 · FY2012 · NS · contact PI
RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells$458,810
R01 · FY2011 · CA · contact PI
ENHANCING GLIOMA IMMUNOTHERAPY WITH TEMODAR-INDUCED LYMPHOPENIA AND A MULTIVALENT$228,970
P50 · FY2011 · NS · contact PI
Pre-clinical Translation of Regulatory T-cell Inhibition in Brain Tumors$196,250
R21 · FY2011 · NS · contact PI
Neuroimmunology of Vaccines in Adoptive T-cell Therapy for Brain Tumor$192,325
R21 · FY2011 · NS · contact PI
NINDS Research Education Programs for Residents and Fellows in Neurosurgery$54,482
R25 · FY2011 · NS · contact PI
NINDS Research Education Programs for Residents and Fellows in Neurosurgery$1
R25 · FY2011 · NS · contact PI
RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells$523,631
R01 · FY2010 · CA · contact PI
ENHANCING GLIOMA IMMUNOTHERAPY WITH TEMODAR-INDUCED LYMPHOPENIA AND A MULTIVALENT$247,202
P50 · FY2010 · NS · contact PI
Pre-clinical Translation of Regulatory T-cell Inhibition in Brain Tumors$235,500
R21 · FY2010 · NS · contact PI
Neuroimmunology of Vaccines in Adoptive T-cell Therapy for Brain Tumor$235,500
R21 · FY2010 · NS · contact PI
Gene Targeted Therapy of Brain Tumors$194,754
R21 · FY2010 · NS · contact PI
NINDS Research Education Programs for Residents and Fellows in Neurosurgery$54,482
R25 · FY2010 · NS · contact PI
NINDS Research Education Programs for Residents and Fellows in Neurosurgery$1
R25 · FY2010 · NS · contact PI
RNA-Based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells$407,160
R01 · FY2009 · CA · contact PI
ENHANCING GLIOMA IMMUNOTHERAPY WITH TEMODAR-INDUCED LYMPHOPENIA AND A MULTIVALENT$303,435
P50 · FY2009 · NS · contact PI
RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells$256,854
R01 · FY2009 · CA · contact PI
Gene Targeted Therapy of Brain Tumors$233,754
R21 · FY2009 · NS · contact PI
Effect on IL-2R Antibody on Regulatory T-cells in Patients with Malignant Gliomas$175,500
R21 · FY2009 · CA · contact PI
Effect on IL-2R Antibody on Regulatory T-cells in Patients with Malignant Gliomas$78,000
R21 · FY2009 · CA · contact PI
NINDS Research Education Programs for Residents and Fellows in Neurosurgery$50,226
R25 · FY2009 · NS · contact PI
RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells$251,093
R01 · FY2008 · CA · contact PI
Effect on IL-2R Antibody on Regulatory T-cells in Patients with Malignant Gliomas$210,600
R21 · FY2008 · CA · contact PI
ENHANCING CMV-SPECIFIC ANTI-TUMOR IMMUNE RESPONSE IN MALIGNANT ASTROCYTOMAS$203,489
P50 · FY2008 · CA · contact PI
ENHANCING CMV-SPECIFIC ANTI-TUMOR IMMUNE RESPONSE IN MALIGNANT ASTROCYTOMAS$213,838
P50 · FY2007 · CA · contact PI
Dendritic Cell Immunotherapy of Malignant Gliomas$300,762
R01 · FY2006 · CA · contact PI
Intracerebral Infusion of Radiolabeled Specific Antibody$300,762
R01 · FY2006 · CA · contact PI
CMV-SPECIFIC ANTI-TUMOR IMMUNE RESPONSE IN ASTROCYTOMAS$128,002
P50 · FY2006 · CA · contact PI
DEUTERATED H2O TO MONITOR DISTRIBUTION OF THERAPEUTIC AGENTS$10,252
P41 · FY2006 · RR · contact PI
Intracerebral Infusion of Radiolabeled Specific Antibody$308,000
R01 · FY2005 · CA
Dendritic Cell Immunotherapy of Malignant Gliomas$308,000
R01 · FY2005 · CA
CMV-SPECIFIC ANTI-TUMOR IMMUNE RESPONSE IN ASTROCYTOMAS$128,005
P50 · FY2005 · CA
DEUTERATED H2O TO MONITOR DISTRIBUTION OF THERAPEUTIC AGENTS$10,662
P41 · FY2005 · RR
Intracerebral Infusion of Radiolabeled Specific Antibody$308,000
R01 · FY2004 · CA
Dendritic Cell Immunotherapy of Malignant Gliomas$305,300
R01 · FY2004 · CA
CMV-SPECIFIC ANTI-TUMOR IMMUNE RESPONSE IN ASTROCYTOMAS$128,135
P50 · FY2004 · CA
MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW$125,496
K23 · FY2004 · RR
Intracerebral Infusion of Radiolabeled Specific Antibody$308,000
R01 · FY2003 · CA
Dendritic Cell Immunotherapy of Malignant Gliomas$305,300
R01 · FY2003 · CA
MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW$125,496
K23 · FY2003 · RR
Intracerebral Infusion of Radiolabeled Specific Antibody$308,000
R01 · FY2002 · CA
Dendritic Cell Immunotherapy of Malignant Gliomas$299,633
R01 · FY2002 · CA
MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW$125,496
K23 · FY2002 · RR
DENDRITIC CELL BASED IMMUNOTHERAPY OF MALIGNANT GLIOMAS$0
P20 · FY2002 · CA
MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW$125,253
K23 · FY2001 · RR
MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW$125,172
K23 · FY2000 · RR